Industry Outlook

Sleep Apnea Devices market accounted for USD 9.4 Billion in 2024 and is expected to reach USD 23.53 Billion by 2035, growing at a CAGR of around 8.7% between 2025 and 2035. Sleep apnea may be a potentially serious sleep disorder characterized by anomalous breathing designs. Individuals with untreated sleep apnea involvement disturbances in their breathing during sleep, which can lead to insufficient oxygen supply to the brain and other parts of the body. This condition is especially common among the elderly and those with basic well-being issues such as diabetes, hypertension, and cardiovascular disorders. Obstructive Rest Apnea (OSA) is the foremost predominant frame globally. Early conclusion and the utilization of therapeutic devices are vital for managing and anticipating complications related to this condition. 

Report Scope:

Market Dynamics

• Increasing Awareness of Sleep Apnea and Its Comorbidities

Sleep apnea is related with several comorbidities, including obesity, diabetes, cardiovascular disease, and hypertension. Around 73% of patients with steady heart disappointment show sleep-disordered breathing, checked by visit scenes of apnea and hypopnea, which disturb standard breathing and adversely affect in general wellbeing. Additionally, sleep apnea could be a critical supporter to hypertension, with the risk of developing high blood weight expanding with the seriousness of sleep-disordered breathing. The developing acknowledgment of these genuine wellbeing suggestions is anticipated to drive more prominent mindfulness and request for rest apnea diagnosis and treatment, in this manner boosting deals within the sleep apnea devices market. 

According to NHLBI, approximately 50% of individuals with congestive heart failure experience sleep-disordered breathing, including both apnea and hypopnea episodes that disrupt normal breathing patterns and compromise overall health. The NHLBI also reports that obstructive sleep apnea is significantly associated with hypertension, noting that individuals with moderate to severe sleep apnea have a markedly higher risk of developing high blood pressure.

• High Price of Sleep Apnea Equipment

The market growth for sleep apnea gadgets faces a few obstacles despite the expanding worldwide predominance of conditions related with a stationary way of life. One major obstacle is the high cost of the hardware. Medicines for obstructive sleep apnea (OSA), such as CPAP and polysomnography (PSG) gadgets, can be costly, with CPAP machines frequently extending from USD 600 to USD 800. Created nations advantage from progressed healthcare frameworks and successful repayment instruments, which encourage access to these gadgets. In any case, developing countries experience challenges such as constrained reimbursement options and high out-of-pocket expenses, which confine understanding access to treatment and contribute to lower coverage rates. 

• Expanding Demand for Home Sleep Apnea Tests (HSATs)

Home sleep apnea tests (HSATs) are gaining notoriety due to their comfort for overseeing sleep apnea from the consolation of domestic. The pandemic has quickened this drift by boosting the selection of telemedicine, which has contributed to showcase extension. Furthermore, advancements in Artificial Insights (AI) and other cutting-edge advances are broadening showcase openings and improving the viability and openness of HSATs. 

The National Sleep Foundation (NSF) provides pertinent statistics illustrating the growing demand for Home Sleep Apnea Tests (HSATs). According to a report by the NSF, there has been a significant increase in the use of HSATs, with a 25% rise in home testing compared to in-lab polysomnography over the past five years. This shift is largely due to the enhanced comfort and convenience of conducting sleep studies at home.

Industry Experts Opinion

"The growing adoption of telemedicine and home sleep apnea tests (HSATs) is significantly enhancing patient management and driving substantial growth in the market."- Philips India: Kris Bhutta, CEO

"Our commitment to advancing healthcare includes exploring innovative solutions for sleep disorders, aiming to improve patient outcomes through cutting-edge technologies."- Narayana Health: Dr. Devi Shetty, Founder and Chairman

Segment Analysis

Based on the product type, the market of Sleep Apnea Devices has been classified into 2 types: Therapeutic Devices and Diagnostic Devices. In therapeutic devices market, they have subsegments such as Continuous Positive Airway Pressure (CPAP) Devices, Bi-Level Positive Airway Pressure (BiPAP) Devices, Adaptive Servo-Ventilation (ASV) Devices, Oral Appliances, Nasal Devices, Positional Therapy Devices. In diagnostic devices market it contains Polysomnography (PSG) Devices, Home Sleep Testing (HST) Devices.

By technology, the Sleep Apnea Devices market is segmented into Pressure Devices, Wearable Sleep Monitors, and Cloud-Connected Devices. Pressure Devices include CPAP, BiPAP, and ASV machines. Wearable Sleep Monitors track sleep patterns through portable technology, while Cloud-Connected Devices facilitate remote monitoring and data analysis via online platforms.

Regional Analysis

Regionally, North America as of now overwhelms the showcase for rest apnea gadgets and is anticipated to preserve this lead all through the figure period. The showcase is expected to be driven by the rising predominance of sleep apnea due to fundamental conditions such as misery and uneasiness, as well as specialized headways and an increment in item dispatches. Concurring to a think about distributed in UpToDate in January 2022, the assessed predominance of rest apnea in North America is 15 to 30% in males and 10 to 15% in females. The same study found that a 10% increment in weight was related with a six-fold increment within the risk of obstructive sleep apnea (OSA). Moreover, investigate distributed by Clocks and Sleep in February 2022 noted the next extent of guys (16.3%) within the direct to serious OSA category compared to females, with 12.9% of direct to extreme OSA members being aged 18-39 a long time. The predominance of weight was found to be 49.4%, with 38% of guys and 58% of females classified as corpulent. The expanding predominance of corpulence is anticipated to drive higher request for sleep apnea gadgets, encourage fueling showcase development over the estimate period. 

Asia-Pacific is rising as the fastest-growing advertise for sleep apnea devices, driven by improved healthcare openness and developing mindfulness of rest clutters. The region's quick development is due to a few variables, counting progressed get to to rest apnea gadgets, headways in healthcare framework, and expanded symptomatic rates. Moreover, government subsidizing and activities pointed at tending to sleep health issues and improving treatment availability in nations like China and India advance contribute to the region's development. 

Competitive Landscape

Key players in the Sleep Apnea Devices market include Koninklijke Philips N.V., ResMed, Fisher & Paykel Healthcare Limited, Invacare Corporation, DeVilbiss Healthcare LLC (a subsidiary of Drive DeVilbiss Healthcare), BMC Medical Co., Ltd., Natus Medical Incorporated, Weinmann Emergency Medical Technology GmbH + Co. KG, SOMNOmedics GmbH, Compumedics Limited, Braebon Medical Corporation, APEX Medical Corporation, Löwenstein Medical GmbH & Co. KG, Circadiance LLC, Curative Medical Inc., Panthera Dental Inc., NovaSom Inc., Inspire Medical Systems, Inc., Advanced Brain Monitoring, Inc., and Itamar Medical Ltd.

Sleep Apnea Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In November 2023, Vivos received U.S. FDA approval for its Vivos CARE (Complete Airway Repositioning and Expansion) oral appliances, designed for patients suffering from obstructive sleep apnea (OSA). This approval allows the company to expand its product portfolio in the sleep apnea market.
• In April 2024, the University of Cincinnati presented the VortexPAP, an unused CPAP system leveraging Vortex wind stream innovation. Preparatory clinical trials have appeared that VortexPAP can provide the same weight levels as conventional CPAP medications, but with a more comfortable veil. Its streamlined plan minimizes prominence and avoids coordinate contact with the patient's face. 

Report Coverage:

By Product Type

• Therapeutic Devices 
  • Continuous Positive Airway Pressure (CPAP) Devices
  • Bi-Level Positive Airway Pressure (BiPAP) Devices
  • Adaptive Servo-Ventilation (ASV) Devices
  • Oral Appliances
  • Nasal Devices
  • Positional Therapy Devices
• Diagnostic Devices
• Polysomnography (PSG) Devices
• Home Sleep Testing (HST) Devices

By Application

• Obstructive Sleep Apnea (OSA)
• Central Sleep Apnea (CSA)
• Complex Sleep Apnea Syndrome

By Distribution

• Hospital Pharmacies
• Retail Pharmacies
• Online

By Technology

• Pressure Devices
• Wearable Sleep Monitors
• Cloud-Connected Devices

By End-user

• Hospitals & Sleep Labs
• Clinics
• Homecare Settings
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Koninklijke Philips N.V.
• ResMed
• Fisher & Paykel Healthcare Limited
• Invacare Corporation
• DeVilbiss Healthcare LLC (a subsidiary of Drive DeVilbiss Healthcare)
• BMC Medical Co., Ltd.
• Natus Medical Incorporated
• Weinmann Emergency Medical Technology GmbH + Co. KG
• SOMNOmedics GmbH
• Compumedics Limited
• Braebon Medical Corporation
• APEX Medical Corporation
• Löwenstein Medical GmbH & Co. KG
• Circadiance LLC
• Curative Medical Inc.
• Panthera Dental Inc.
• NovaSom Inc.
• Inspire Medical Systems, Inc.
• Advanced Brain Monitoring, Inc.
• Itamar Medical Ltd.
• Top of Form
• Bottom of Form

Frequently Asked Questions (FAQs)